Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance

NASHVILLE--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the following select preliminary second quarter 2023 financial guidance: Second quarter 2023 revenues in excess of $31.0 million compared with prior-year second quarter revenues of $23.3 million Second quarter 2023 Adjusted EBITDA (a non-GAAP measure) in excess of $9.3 million Management expects to release full second quarter 2023 financial results on August 9, 2023. About Harrow Ha